Lupinacci Renato Micelli, Paye François, Coelho Fabricio Ferreira, Kruger Jaime Arthur Pirolla, Herman Paulo
Service de chirurgie Digestive, viscérale et endocrinienne, Groupe Hospitalier Diaconesses Croix-Saint-Simon, 125, rue d'Avron, 75020, Paris, France,
Updates Surg. 2014 Dec;66(4):239-45. doi: 10.1007/s13304-014-0265-0. Epub 2014 Aug 29.
The liver is the most common site of distant metastases in patients with colorectal cancer. Surgery represents the mainstream for curative treatment of colorectal cancer liver metastases (CRCLM) with long-term survival up to 58 and 36 % at 5 and 10 years, respectively. Despite advances on diagnosis, staging and surgical strategies, 60-70 % of patients will develop recurrence of the disease even after R0 resection of CRCLM. Tumor staging, prognosis, and therapeutic approaches for cancer are most often based on the extent of involvement of regional lymph nodes (LNs) and, to a lesser extent, on the invasion of regional lymphatic vessels draining the primary tumor. For CRCLM, the presence of intra hepatic lymphatic and blood vascular dissemination has been associated with an increased risk of intra hepatic recurrence, poorer disease-free and overall survival after liver resection. Also, several studies have reviewed the role of surgery in the patient with concomitant CRCLM and liver pedicle LN metastasis. Although pedicle LN involvement is related to worst survival rates, it does not differentiate patients that will relapse from those that will not. This review aims to briefly describe the anatomy of the liver's lymphatic drainage, the incidence of intrahepatic lymphatic invasion and hilar lymph node involvement, as well as their clinical impact in CRCLM. A better understanding of the role of liver lymphatic metastasis might, in the near future, impact the strategy of systemic therapies after liver resection as for primary colorectal tumors.
肝脏是结直肠癌患者远处转移最常见的部位。手术是治疗结直肠癌肝转移(CRCLM)的主流方法,5年和10年的长期生存率分别高达58%和36%。尽管在诊断、分期和手术策略方面取得了进展,但即使在CRCLM进行R0切除后,仍有60%-70%的患者会出现疾病复发。癌症的肿瘤分期、预后和治疗方法通常基于区域淋巴结(LN)的受累程度,在较小程度上基于引流原发肿瘤的区域淋巴管的侵犯情况。对于CRCLM,肝内淋巴和血管播散的存在与肝内复发风险增加、肝切除术后无病生存期和总生存期较差有关。此外,多项研究回顾了手术在伴有CRCLM和肝蒂LN转移患者中的作用。虽然肝蒂LN受累与最差的生存率相关,但它并不能区分哪些患者会复发,哪些患者不会复发。本综述旨在简要描述肝脏淋巴引流的解剖结构、肝内淋巴侵犯和肝门淋巴结受累的发生率,以及它们在CRCLM中的临床影响。更好地理解肝脏淋巴转移的作用,在不久的将来,可能会影响肝切除术后的全身治疗策略,如同原发性结直肠癌肿瘤一样。